Cancer-associated thrombosis: An update

Drug Discovery Today: Disease Mechanisms

Volumn 8, Issue 1-2, 2011, Pages

  Shelke, Abhay R ^a   Khorana, Alok A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ARGATROBAN; BEMIPARIN; BEVACIZUMAB; D DIMER; DABIGATRAN; DALTEPARIN; DOXORUBICIN; DX 9065 A; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; IDRAPARINUX; LENALIDOMIDE; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PADGEM PROTEIN; SEMULOPARIN; SORAFENIB; STEROID; SUNITINIB; THALIDOMIDE; THROMBOPLASTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; CANCER ASSOCIATED THROMBOSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CAUSE OF DEATH; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; INCIDENCE; LIVER TOXICITY; LONG TERM CARE; MYELOMA; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SOLID TUMOR; SURVIVAL RATE; THROMBOCYTE ACTIVATION; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84859790328     PISSN: None     EISSN: 17406765     Source Type: Journal    
DOI: 10.1016/j.ddmec.2012.02.001     Document Type: Review

References (47)

1. Khorana, A.A. et al. (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Hemost. 5, 632-634 (Pubitemid 46680709)
2. Heit, J.A. et al. (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med. 160, 809-815 (Pubitemid 30165241)
3. Kahn, S.R. et al. (2005) Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch. Intern. Med. 165, 1173-1178 (Pubitemid 40720743)
4. Elting, L.S. et al. (2004) Outcomes and cost of deep venous thrombosis among patients with cancer. Arch. Intern. Med. 164, 1653-1661 (Pubitemid 39037944)
5. Yu, J.L. et al. (2005) Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105, 1734-1741 (Pubitemid 40223697)
6. Mackman, N. (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler. Thromb. Vasc. Biol. 24, 1015-1022
7. Piccin, A. et al. (2007) Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 21, 157-171 (Pubitemid 46529055)
8. Khorana, A.A. et al. (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin. Cancer Res. 13, 2870-2875 (Pubitemid 46849560)
9. Khorana, A.A. (2011) Risk assessment and prophylaxis for VTE in cancer patients. J. Natl. Compr. Canc. Netw. 9, 789-797
10. Andrea, N. et al. (2003) Management of thrombosis in the cancer patient. J. Support. Oncol. 1, 235-238
11. Bambace, N.M. et al. (2011) The platelet contribution to cancer progression. J. Thromb. Haemost. 9, 237-249
12. Nierodzik, M.L. et al. (1995) Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb. Haemost. 74, 282-290
13. Fontaine, E. et al. (2010) Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur. J. Cardiothorac. Surg. 38, 21-26
14. Rothwell, P.M. et al. (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 376, 1741-1750
15. Sousou, T. et al. (2009) New insights into cancer-associated thrombosis. Arterioscler. Thromb. Vasc. Biol. 29, 316-320
16. Zwicker, J.I. et al. (2007) Cancer-associated thrombosis. Crit. Rev. Oncol. Hematol. 62, 126-136 (Pubitemid 46575277)
17. Khorana, A.A. et al. (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110, 2339-2346 (Pubitemid 350100757)
18. Blom, J.W. et al. (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293, 715-722 (Pubitemid 40216041)
19. van Doormaal, F.F. et al. (2010) Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb. Haemost. 104, 86-91
20. Scappaticci, F.A. et al. (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl. Cancer Inst. 99, 1232-1239 (Pubitemid 47299901)
21. Hurwitz, H.I. et al. (2011) Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J. Clin. Oncol. 29, 1757-1764
22. Nalluri, S.R. et al. (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300, 2277-2285
23. Choueiri, T.K. et al. (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J. Clin. Oncol. 28, 2280-2285
24. Khorana, A.A. et al. (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111, 4902-4907
25. Gale, A.J. et al. (2001) Update on tumor cell procoagulant factors. Acta Haematol. 106, 25-32 (Pubitemid 32830513)
26. Ay, C. et al. (2010) Prediction of venous thromboembolism in cancer patients. Blood 116, 5377-5382
27. Samama, M.M. et al. (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N. Engl. J. Med. 341, 793-800 (Pubitemid 29420474)
28. Leizorovicz, A. et al. (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110, 874-879 (Pubitemid 39096017)
29. Cohen, A.T. et al. (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332, 325-329
30. Lyman, G.H. et al. (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 25, 5490-5505 (Pubitemid 350232226)
31. Wagman, L.D. et al. (2008) Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 6, 716-753
32. Lassen, M.R. et al. (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. 363, 2487-2498
33. Kakkar, V.V. et al. (2010) Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J. Thromb. Haemost. 8, 1223-1229
34. Rasmussen, M.S. et al. (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J. Thromb. Haemost. 4, 2384-2390 (Pubitemid 44575433)
35. Lassen, M.R. et al. (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost. 5, 2368-2375 (Pubitemid 350154345)
36. Agnelli, G. et al. (2011) The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, 4-8 June 2011 (abstract no.: LBA9014)
37. Lee, A.Y.Y. et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349, 146-153 (Pubitemid 36818784)
38. Akl, E.A. et al. (2011) Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst. Rev. 4, CD006649
39. Schulman, S. et al. (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342-2352
40. Bauersachs, R. et al. (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 23, 2499-2510
41. Mousa, S.A. (2010) Novel anticoagulant therapy: principle and practice. Methods Mol. Biol. 663, 157-179
42. Poller, L. et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 2673-2674
43. Gomez-Outes, A. et al. (2011) New parenteral anticoagulants in development. Therap. Adv. Cardiovasc. Dis. 5, 33-59
44. Ruff, C.T. et al. (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective azNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J. 160, 635-641
45. Turpie, A.G.G. et al. (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373, 1673-1680
46. Turpie, A.G.G. et al. (2009) A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb. Haemost. 101, 68-76
47. Abraham, E. et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290, 238-247 (Pubitemid 37430063)